| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-01-19 | uniQure (The Netherlands) 4D Molecular Therapeutics (USA - CA) | adeno-associated viral (AAV) vector discovery and optimization technology for gene delivery to the central nervous system and liver. | licensing collaboration |
CNS diseases - Liver diseases - Hepatic diseases | Licensing agreement | |
| 2014-01-17 | Axxam (Italy) Cellectis bioresearch (France) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2014-01-17 | Shire (UK-USA) Organogenesis (USA) | Dermagraft® assets | diabetic foot ulcers | product acquisition |
Metabolic diseases | Product acquisition |
| 2014-01-16 | Horizon Discovery (UK) Transgenomic (USA) | improved genetic diagnostic tests | collaboration |
Diagnostic | Collaboration agreement | |
| 2014-01-15 | Sanofi (France) Fraunhofer-Gesellschaft (Germany) | natural product center of excellence | infectious diseases | R&D |
Infectious diseases | R&D agreement |
| 2014-01-15 | Helsinn (Switzerland) Angelini (Italy) | anamorelin | anorexia-cachexia in non small lung cell cancer (NSLC) | commercialisation |
Cancer - Oncology | Commercialisation agreement |
| 2014-01-14 | Genmab (Denmark) Lilly (USA - IN) | DuoBody™ technology platform for the creation of bispecific antibodies | R&D |
Technology - Services | R&D agreement | |
| 2014-01-14 | Ipsen (France) GW Pharmaceutical (UK) | Sativex® (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD) | spasticity due to multiple sclerosis | promotion |
Neurodegenerative diseases | Distribution agreement |
| 2014-01-14 | Onkaido Therapeutics, Moderna Therapeutics' company (USA - MA) | vice president | nomination | Cancer - Oncology | Nomination | |
| 2014-01-13 | AstraZeneca (UK) Ardelyx (USA) | NHE3 inhibitor programme including tenapanor, RDX5791 | complications of renal disease, including diabetes-induced renal disease, chronic kidney disease | licensing |
Kidney diseases - Renal diseases - Metabolic diseases | Milestone |
| 2014-01-13 | Cell Therapeutics (USA) Novartis (Switzerland) | Opaxio™ (paclitaxel poliglumex), Pixuvri® (pixantrone) | multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma | licensing |
Cancer - Oncology | Licensing agreement |
| 2014-01-13 | Bayer (Germany) Regeneron Pharmaceuticals (USA - NY) | Platelet Derived Growth Factor Receptor Beta (PDGFR-Beta) antibody potential combination therapy with Eylea® (aflibercept) | wet age-related macular degeneration (wet AMD) | development |
Ophtalmological diseases | Development agreement |
| 2014-01-13 | Diaxonhit (France) Samsung (South Korea) | point of care diagnostic tests (IB10, PT10 and HC10 equipment together with associated reagents) | distribution |
Distribution agreement | ||
| 2014-01-13 | Jazz Pharmaceuticals (Ireland) Aerial Biopharma (USA) | ADX-N05 | excessive daytime sleepiness in patients with narcolepsy | licensing |
Rare diseases | Licensing agreement |
| 2014-01-13 | Prosensa (The Netherlands) GSK (UK) | drisapersen (previously GSK2402968/PRO051) and other DMD programmes | Duchenne muscular dystrophy | licensing |
Genetic diseases - Neuromuscular diseases - Rare diseases | Termination of an agreement |
| 2014-01-13 | Argen-X (The Netherlands-Belgium) Boehringer Ingelheim (Germany) | R&D |
undisclosed | R&D agreement | ||
| 2014-01-13 | Galapagos (Belgium) Mimetas (The Netherlands) | organ-on-a-chip-based human disease models | R&D |
Technology - Services | R&D agreement | |
| 2014-01-13 | Lonza (Switzerland) Pharmacyclics (USA) | Imbruvica™ (ibrutinib) | manufacturing |
Cancer - Oncology | Production agreement | |
| 2014-01-13 | Trianta Immunotherapies (Germany) Ascenion (Germany) | personalized dendritic cell vaccines and adoptive T-cell therapies | licensing |
Cancer - Oncology | Licensing agreement | |
| 2014-01-13 | UCB (Belgium) MRC Technology (UK) | fibrosis therapy program | fibrosis | development |
Development agreement |
